Core Insights - The event features a virtual fireside chat with Yujiro Hata, CEO of IDEAYA, hosted by Yigal Nochomovitz, a biotech analyst at Citigroup [1][2] Group 1 - The discussion is part of a series aimed at engaging with C-suite executives in the biotech industry [1] - Participants are encouraged to submit questions for the CEO during the conversation [2]

Summary of IDEAYA Biosciences Conference Call Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Date**: November 06, 2025 - **Context**: Discussion led by CEO Yujiro Hata regarding recent developments in the company's pipeline and strategic direction. Key Industry and Company Insights Pipeline Developments - IDEAYA reported one of its most productive quarters since its founding, with significant updates presented at major medical conferences, including the World Conference on Lung Cancer and ESMO [3][4] - The lead program is nearing randomized progression-free survival (PFS) results, with expectations for an accelerated approval filing in the U.S. by year-end or early next year [3][4] - Enrollment for clinical trials is progressing well, with full enrollment expected soon for both overall survival (OS) and randomized OS studies [4] Uveal Melanoma Focus - IDEAYA aims for darovasertib to become the standard of care across the uveal melanoma patient journey, with plans for a phase three randomized study in the adjuvant setting in the first half of next year [7][9] - The annual incidence of metastatic uveal melanoma is estimated at 4,000-5,000 patients, with potential for higher numbers in neoadjuvant and adjuvant settings [7][8] - The company has received Breakthrough Therapy Designation from the FDA based on promising data from clinical cohorts [10] Clinical Trial Data and Expectations - In the enucleation cohort, the eye preservation rate exceeded the 10% threshold required for full approval, indicating strong efficacy [10][11] - The plaque therapy cohort showed a median vision improvement of 14 letters, significantly higher than previous reports [11] - The company anticipates that the first data from the enucleation cohort will be available in approximately five quarters, with visual acuity results expected 18 months after the last patient is enrolled [19][20] MTAP Deletion Market - IDEAYA is focusing on MTAP deletion across multiple tumor types, prioritizing lung cancer, urothelial cancer, and pancreatic ductal adenocarcinoma (PDAC) [35] - The confirmed response rate for ID 397 in monotherapy is in the 25-30% range, with combination therapy showing a response rate of approximately 50% [37][38] - The company is exploring co-alterations in MTAP, particularly with RAS and CDK N2A, to enhance treatment efficacy [50][51] DLL3 Asset Development - IDEAYA's DLL3 ADC has shown a confirmed response rate of 70% in the second-line setting, with a PFS of approximately 6.7 months [55] - The company is considering a monotherapy accelerated approval path, which could provide a competitive advantage over other companies requiring comparator arms [57] Other Assets and Future Directions - IDEAYA is advancing several other assets, including poltheta partnered with GSK, and a bispecific ADC targeting B7H3 and PTK7, which has shown promising preclinical results [63][64] - The company is leveraging machine learning to enhance drug discovery efficiency, aiming for a 30% acceleration in time to IND [73][74] Additional Important Points - The collaboration with the FDA has been positive, allowing for adjustments in trial design that reduce patient enrollment numbers without compromising study integrity [24] - The company is focused on building a world-class precision oncology portfolio and is actively seeking partnerships to advance its pipeline [66] This summary encapsulates the key points discussed during the conference call, highlighting IDEAYA Biosciences' strategic focus, pipeline advancements, and market opportunities.

Financial Performance - Total revenue for the three months ended September 30, 2025, was $207.834 million, compared to $0 for the same period in 2024[17] - Net income for the three months ended September 30, 2025, was $119.244 million, compared to a net loss of $51.821 million in the same period of 2024[17] - For the nine months ended September 30, 2025, the net loss was $30.4 million, compared to a net loss of $144.2 million for the same period in 2024[26] - Net income attributable to common stockholders for Q3 2025 was $119,244,000, compared to a loss of $51,821,000 in Q3 2024[162] - Basic net income per share for Q3 2025 was $1.35, while in Q3 2024 it was $(0.60)[162] Revenue and Collaboration - The company reported collaboration revenue of $207.834 million for the three months ended September 30, 2025[17] - The Company recognized $207.8 million in collaboration revenue related to the Servier License Agreement for the three and nine months ended September 30, 2025[141] - The remaining performance obligation under the Servier License Agreement was $143.1 million as of September 30, 2025, with $32.4 million expected to be satisfied over the next 12 months[146] - The Company has the potential to earn up to $475.0 million in commercial milestones from GSK upon commercialization of Pol Theta and Werner Helicase products[109][114] - The Company has the potential to achieve additional late-stage development and regulatory milestones of up to $465 million under the GSK Collaboration Agreement[156] Expenses and Costs - Research and development expenses for the nine months ended September 30, 2025, were $228.105 million, an increase of 47.5% from $154.490 million in 2024[17] - Operating expenses for the three months ended September 30, 2025, totaled $99.382 million, compared to $66.893 million in the same period of 2024[17] - Total research and development expenses for Q3 2025 were $82,993,000, an increase from $57,152,000 in Q3 2024, representing a 45% increase[166] - Stock-based compensation increased to $34.3 million for the nine months ended September 30, 2025, compared to $25.3 million for the same period in 2024[26] - Total stock-based compensation expense for the nine months ended September 30, 2025, was $34.3 million, compared to $25.3 million for the same period in 2024, a 35.7% increase[97] Assets and Cash Position - Total assets as of September 30, 2025, were $1.185 billion, an increase from $1.124 billion as of December 31, 2024[15] - Cash and cash equivalents increased to $298.927 million as of September 30, 2025, from $84.378 million as of December 31, 2024[15] - The company had cash, cash equivalents, and marketable securities of approximately $1.14 billion as of September 30, 2025[232] - The company had cash, cash equivalents, and marketable securities of approximately $1.14 billion as of September 30, 2025, which is expected to fund operations for at least 12 months[35] Liabilities and Deficits - The company had an accumulated deficit of $653.3 million as of September 30, 2025[33] - Accrued liabilities increased to $45.258 million as of September 30, 2025, compared to $30.352 million as of December 31, 2024, with significant increases in accrued research and development expenses from $19.956 million to $32.878 million[68] Stock and Shares - The weighted-average common shares outstanding, basic, for the three months ended September 30, 2025, were 88,526,781, compared to 86,188,510 for the same period in 2024[17] - As of September 30, 2025, the company had reserved a total of 19,174,198 shares of common stock for future issuance, an increase from 13,027,922 shares as of December 31, 2024[85] - The number of shares available for issuance under the 2023 Inducement Plan was 1,426,467 as of September 30, 2025, following amendments that increased the number of shares available[88] Regulatory and Market Risks - The Company operates in a highly competitive biotechnology industry and faces risks such as dependence on key personnel and the need for additional financing[40] - The Company is subject to regulatory approvals from the FDA and other agencies before commercial sales can occur, impacting the timeline for revenue generation[41] - Significant funds are required for research, development, and clinical testing of product candidates, with the Company unable to fully fund these efforts with current financial resources[43] Future Commitments and Agreements - The Company entered into a lease agreement for approximately 44,000 square feet of laboratory and office facilities, with a lease term of 120 months starting in August 2024[69] - Future minimum lease payments under operating leases total $46.455 million as of September 30, 2025, with total operating lease liabilities of $27.245 million after deducting imputed interest[72] - The Company is currently evaluating the impact of new accounting pronouncements, including ASU 2023-06 and ASU 2023-09, on its financial disclosures[50][51]

Financial Performance - IDEAYA reported collaboration revenue of $207.8 million for Q3 2025, compared to zero in Q2 2025, primarily due to the Servier license agreement[13] - The net income for Q3 2025 was $119.2 million, a significant improvement from a net loss of $77.5 million in Q2 2025[16] - Collaboration revenue for the three months ended September 30, 2025, was $207.834 million, with total revenue matching this figure[23] - Net income for the three months ended September 30, 2025, was $119.244 million, compared to a net loss of $77.491 million in the previous quarter[23] - Comprehensive income for the three months ended September 30, 2025, was $119.775 million, contrasting with a comprehensive loss of $77.555 million in the previous quarter[23] - The company reported a net income per share attributable to common stockholders of $1.35 for the three months ended September 30, 2025[23] Cash and Assets - As of September 30, 2025, IDEAYA had approximately $1.14 billion in cash, cash equivalents, and marketable securities, up from $991.9 million as of June 30, 2025[12] - Cash and cash equivalents, along with marketable securities, totaled $1.136 billion as of September 30, 2025, up from $1.082 billion at the end of 2024[25] - Total assets increased to $1.185 billion as of September 30, 2025, compared to $1.124 billion at the end of 2024[25] - Total liabilities rose to $93.102 million as of September 30, 2025, from $64.944 million at the end of 2024[25] Expenses - Research and development expenses for Q3 2025 totaled $83.0 million, an increase from $74.2 million in Q2 2025, driven by higher clinical trial costs[14] - General and administrative expenses for Q3 2025 were $16.4 million, up from $14.6 million in Q2 2025, mainly due to increased legal and commercial preparation expenses[15] - Research and development expenses for the same period were $82.993 million, an increase from $74.226 million in the previous quarter[23] Clinical Development - IDEAYA completed its third IND filing in 2025, further extending its leadership in precision medicine oncology[3] - The Phase 2/3 trial of darovasertib/crizotinib in metastatic uveal melanoma is on track to report median progression-free survival data by year-end 2025 to Q1 2026[5] - The company reported a median overall survival of 21.1 months and a median progression-free survival of 7.0 months in the Phase 2 trial of darovasertib[6] - IDEAYA plans to initiate a global Phase 3 trial of darovasertib and crizotinib as an adjuvant therapy for primary uveal melanoma in the first half of 2026[8] Licensing and Collaboration - IDEAYA entered into an exclusive license agreement with Servier for darovasertib outside the U.S., receiving an upfront payment of $210 million and potential milestone payments of up to $320 million[11] Risks and Uncertainties - IDEAYA's forward-looking statements highlight potential risks and uncertainties in drug development and regulatory processes[19]

Core Insights - IDEAYA Biosciences reported significant progress in its pipeline and business operations, including a partnership with Servier that extends its runway into 2030 and enables potential commercialization of darovasertib outside the U.S. [2] Pipeline Developments - The Phase 2/3 trial (OptimUM-02) of darovasertib/crizotinib in metastatic uveal melanoma is on track to report median progression-free survival (PFS) data by year-end 2025 to Q1 2026, with enrollment expected to be completed by year-end [4][5] - The single-arm Phase 2 trial (OptimUM-01) reported a median overall survival (OS) of 21.1 months and a median PFS of 7.0 months, with a confirmed overall response rate (ORR) of 34% [5] - IDEAYA has initiated a randomized Phase 3 trial (OptimUM-10) for darovasertib as a neoadjuvant therapy in primary uveal melanoma, targeting approximately 450 patients [8] Financial Highlights - As of September 30, 2025, IDEAYA had approximately $1.14 billion in cash, cash equivalents, and marketable securities, an increase from $991.9 million as of June 30, 2025, primarily due to a $210 million upfront payment from Servier [11] - Collaboration revenue for Q3 2025 totaled $207.8 million, compared to zero in the previous quarter, driven by the Servier license agreement [11] - The net income for Q3 2025 was $119.2 million, a significant improvement from a net loss of $77.5 million in Q2 2025 [14] License Agreement with Servier - IDEAYA entered into an exclusive license agreement with Servier for darovasertib outside the U.S., receiving an upfront payment of $210 million and being eligible for up to $320 million in milestone payments [10] Research and Development Expenses - R&D expenses for Q3 2025 totaled $83.0 million, an increase from $74.2 million in Q2 2025, primarily due to higher clinical trial and manufacturing expenses [12] General and Administrative Expenses - G&A expenses for Q3 2025 were $16.4 million, up from $14.6 million in Q2 2025, mainly due to increased legal and commercial preparation expenses [13]

Group 1 - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It mentions that users with ad-blockers may face restrictions when trying to access the content [1]

Core Insights - IDEAYA Biosciences, Inc. is actively participating in investor relations events, showcasing its commitment to engaging with the investment community [1][3] - The company focuses on precision medicine in oncology, aiming to develop targeted therapies that are tailored to the genetic drivers of cancer [2] Group 1: Investor Relations Events - IDEAYA will participate in Citi's 2025 SMID Cap Biopharma Call Series on November 6, 2025, featuring a fireside chat with CEO Yujiro S. Hata [1] - The company will also be present at the Jefferies Global Healthcare Conference in London on November 18, 2025, with another fireside chat led by CEO Yujiro S. Hata [1] - Live audio webcasts of these events will be available on IDEAYA's website, with replays accessible for 30 days post-event [1] Group 2: Company Overview - IDEAYA is dedicated to the discovery, development, and commercialization of transformative cancer therapies [2] - The company integrates small-molecule drug discovery, structural biology, and bioinformatics to create targeted therapies [2] - IDEAYA has developed a robust pipeline focused on synthetic lethality and antibody-drug conjugates for specific solid tumor indications [2]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Group 1 - Top Wall Street analysts have revised their outlook on several prominent companies, indicating a shift in market sentiment [1] - The article suggests that investors consider buying CRWD stock, highlighting analysts' positive views on its potential [1]

Core Insights - IDEAYA Biosciences presented positive clinical data from the Phase 2 OptimUM-09 trial of neoadjuvant darovasertib for primary uveal melanoma, highlighting its potential as the first systemic therapy for this condition [1][2][10] Clinical Trial Data - The trial involved 95 primary uveal melanoma patients, with 94 evaluable for efficacy as of June 13, 2025 [2] - 83% of patients demonstrated ocular tumor shrinkage, with 54% achieving at least 20% tumor shrinkage [5][10] - Among patients recommended for enucleation, the eye preservation rate was 57%, increasing to 95% for those achieving 20% tumor shrinkage [5][10] - 70% of plaque brachytherapy eligible patients showed a reduction in predicted radiation dose, leading to a 65% lower risk of vision loss at three years post-treatment [5][10] Visual Acuity Improvement - Approximately 55% of enucleation eligible patients and 61% of plaque brachytherapy eligible patients showed improvement in visual acuity scores during treatment, with mean gains of 17 and 10 letters, respectively [5][10] Safety Profile - Darovasertib was generally well tolerated, with manageable adverse events; 16.8% of patients experienced grade 3 or higher treatment-related adverse events [10] Future Developments - IDEAYA is conducting a Phase 3 trial (OptimUM-10) of darovasertib and plans to report topline median progression-free survival data from another trial (OptimUM-02) by the end of 2025 to Q1 2026 [7][10]